NEW YORK (GenomeWeb News) - Mercury Therapeutics said yesterday that it has granted Millipore exclusive worldwide rights to human AMP-activated protein kinase in the field of research products and services.

The AMPK patent was originally licensed by Mercury Therapeutics in 2000 from Dartmouth College. The patent is based on research by Dartmouth professor Lee Witters and his collaborator Bruce Kemp from the St. Vincent's Institute for Medical Research in Melbourne, Australia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.